Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.